Great Point Partners’s Enanta Pharmaceuticals ENTA Stock Holding History

Great Point Partners’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-143,481	Closed	-$10.2M	–	44
2018 Q4	$10.2M	Sell	143,481 -66,919	-32%	-$5.13M	1.28%	26
2018 Q3	$18M	Buy	+210,400	New	+$21.1M	2.8%	18
2017 Q1	–	Sell	-828,253	Closed	-$27.7M	–	42
2016 Q4	$27.7M	Buy	828,253 +38,253	+5%	+$1.1M	5.7%	7
2016 Q3	$21M	Buy	790,000 +251,976	+47%	+$5.85M	5.36%	8
2016 Q2	$11.9M	Buy	+538,024	New	+$14.1M	3.4%	11
2015 Q3	–	Sell	-35,000	Closed	-$1.57M	–	38
2015 Q2	$1.57M	Sell	35,000 -65,000	-65%	-$2.53M	0.61%	29
2015 Q1	$3.06M	Buy	+100,000	New	+$3.89M	1.35%	21

Other funds holding ENTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Great Point Partners's ENTA Position: Q1 2019 in Review

Great Point Partners sold out of Enanta Pharmaceuticals (ENTA) in Q1 2019, closing a stake of 143,481 shares — an estimated $10.2M sold.

Great Point Partners first reported a position in ENTA in Q1 2015 and held it in 7 quarters. The position peaked at $27.7M in Q4 2016. 195 funds tracked by Wall St. Rank hold ENTA as of Q1 2019.

Great Point Partners reported no remaining Enanta Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Great Point Partners sold 143,481 Enanta Pharmaceuticals shares in Q1 2019, an estimated $10.2M.
Great Point Partners first reported a position in Enanta Pharmaceuticals in Q1 2015 and held it in 7 quarters.
Great Point Partners's Enanta Pharmaceuticals position peaked at $27.7M in Q4 2016.
195 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2019.

Based on Great Point Partners's 13F filing for Q1 2019, filed 14 May 2019.